c‐FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma

BACKGROUND: The immunomodulatory drug lenalidomide, which is now widely used for the treatment of multiple myeloma (MM), exerts pharmacological action through the ubiquitin‐dependent degradation of IKZF1 and subsequent down‐regulation of interferon regulatory factor 4 (IRF4), a critical factor for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Osada, Naoki, Kikuchi, Jiro, Iha, Hidekatsu, Yasui, Hiroshi, Ikeda, Sho, Takahashi, Naoto, Furukawa, Yusuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426395/
https://www.ncbi.nlm.nih.gov/pubmed/37581569
http://dx.doi.org/10.1002/ctm2.1364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426395/
https://www.ncbi.nlm.nih.gov/pubmed/37581569
http://dx.doi.org/10.1002/ctm2.1364

Ejemplares similares